SeltaSquare Achieves 'AA' Rating in KIBO Technology Evaluation… "Leading Innovation in AI-Based Pharmacovigilance"
페이지 정보
본문
SeltaSquare, an AI-based digital healthcare company, announced on the 19th that it has received an AA rating in a technology evaluation conducted by the Korea Technology Finance Corporation (KIBO), a designated expert evaluation institution of the Korea Exchange (KRX).
KIBO's technology evaluation system comprises a total of 14 rating tiers, ranging from the highest rating of AAA down to D. An AA rating signifies the highest tier of technological capability and innovation, indicating that the company holds a strong competitive position in its field.
SeltaSquare's AI/DX-based full-lifecycle safety monitoring platform technology dramatically improves the efficiency and accuracy of pharmacovigilance operations. Labor-intensive tasks — such as data monitoring, entry, and analysis — that previously required significant time investment from specialized professionals can now be automated through the SeltaSquare platform.
In particular, SELTA-WAVE standardizes data from diverse sources into a safety data structure, regardless of format or file type, resolving the complex data entry challenges associated with existing Safety Databases in a matter of seconds. Furthermore, through a partnership agreement with Oracle — the world's leading database company — SELTA-WAVE has been integrated with Oracle Safety DB Argus, positioning it as a compelling practical alternative for the PV industry.
CEO Shin Min-kyung stated: "We have built a high barrier to entry by converting the specialized pharmacovigilance expertise of medical and pharmaceutical professionals — including physicians, pharmacists, and master's and doctoral degree holders — into core proprietary technology unique to SeltaSquare. We will continue to contribute to building a better future through ongoing technological innovation and global partnerships."
Read the Original Article on Business Korea: SeltaSquare Achieves 'AA' Rating in KIBO Technology Evaluation… "Leading Innovation in AI-Based Pharmacovigilance"
